About Pharma IPR USA 2019
Intellectual Property (IP) is the backbone to ensure development of new treatments and cures. IP is extremely vital to improvise patient care, spurring economic growth and intensifying the innovation economy. In order to motivate researchers to explore new areas of medical innovation, modern IP systems and strong protections are crucial. The US pharmaceutical & biopharmaceutical industry drives the nation’s Research and Development (R&D) economy, thereby keeping the country at the forefront of advanced technology development. The pharma and Biopharma industry hence is a key generator of new IP’s across the globe.
The industry’s R&D segment has generated stupendous growth in the past decades fuelled by increasing burden of disease. In order for the innovators and the generic industry to maximize its true potential, ideation, innovation and integration are pre-requisites to reaching this stupendous growth. The numerous innovations leading to discovery of new life-saving drugs are through intellectual property rights (IPRs). IPR is a requirement for pharma companies for identification, planning, commercialization and protection of invention. The intellectual property market has manifested growth at an unprecedented pace. Risks abound and rights holders need strategic knowledge to maximize their success in the jurisdiction.
With this overarching global theme of Ideate and Innovate, CPhI Conferences building on the strong momentum of Pharma IPR India is pleased to launch the premier edition of Pharma IPR USA scheduled on 7th-8th November 2019 at Sofitel, New York. Driven by powerful content and unmatched speaker profiles, the forum promises to provide an exceptional opportunity to bring all key stakeholders, IP Attorneys and Counsels from across the globe on a single platform to discuss, deliberate and share their thoughts on achieving the next phase of growth, recent trends and best practices in the Pharma IPR space!